|Home | About | Journals | Submit | Contact Us | Français|
Diabetes mellitus is a major risk factor to impair endothelial function and induce cardiovascular diseases. TNF-alpha (TNF) is expressed during a variety of inflammatory conditions. We hypothesized that impairment in coronary endothelial function in type 2 diabetes is due to the overexpression of TNF and TNF receptors (TNFRs). Endothelium-dependent (acetylcholine, ACh) and –independent vasodilation (sodium nitroprusside, SNP) of isolated, pressurized (60 cmH2O) coronary arteries (50–100 μm) from lean control and Zucker diabetic fatty (ZDF, the model of type 2 diabetes) rats were determined. In lean rats, SNP and ACh induced dose-dependent vasodilation, but dilation to only ACh was blocked by the NOS inhibitor NG-monomethyl-L-arginine (L-NMMA, 10 μM). In ZDF rats, dilation to ACh was blunted compared to lean rats, but SNP-induced dilation was comparable. Neutralizing antibodies to TNF, or blockade of NAD(P)H and xanthine oxidase, partially restored endothelium-dependent, NO-mediated vasodilation in isolated coronary arteries in ZDF rats, but anti-TNF did not alter endothelium-dependent vasodilation in lean rats. The mRNA expression of TNF receptor 1 (TNFR1, but not TNFR2) significantly increased in coronary arteries in ZDF rats. Protein expression of TNF and N-Tyr (ONOO−) were higher in coronary arteries in ZDF than those in lean rats. Production of H2O2, NAD(P)H oxidase and xanthine oxidase activity were all higher in ZDF rats than those in lean controls; anti-TNF reduces the production of H2O2, N-Tyr expression, NAD(P)H oxidase and xanthine oxidase activity in ZDF rats. These results demonstrate the endothelial dysfunction occurring in type 2 diabetes is the result of effects of the inflammatory cytokine TNF that activates NAD(P)H oxidase and xanthine oxidase; and perhaps acts mainly through the overexpression of TNFR1.
Diabetes mellitus is associated with a significant increase incidence in the development of cardiovascular diseases. Vascular disease, particularly of the coronary arteries, is the major cause of morbidity and mortality in type 2 diabetic subjects (4). Diabetes impaired endothelium-dependent relaxation in rabbit aorta in vitro (21, 22), and the cerebral circulation in vivo (10, 11). Function of vasodilation in intestinal and skeletal muscle vessels were decreased in type 2 diabetes (8, 13). However, few investigations into the dysfunction of heart coronary arteries have been conducted in diabetes. TNF is one of the key inflammatory mediators expressed during a variety of inflammatory conditions, and takes part in a variety of physiological and pathological phenomena. For example, TNF expression was increased in coronary arteries in hyperhomocysteinemia, an independent risk factor for coronary artery disease (15, 19). The titer of TNF in circulation increased in weight-gaining rats, but decreased in weight-losing rats (6).
TNF initiates inflammatory responses by binding to two distinct cell surface receptors of 55 kDa (TNFR1) and 75 kDa (TNFR2) (20). The increase in membrane and soluble receptors together with an increase in the presence TNF could increase signaling activity into cells. However, little information is available regarding the role of TNF in endothelial dysfunction of coronary arteries in advanced type 2 diabetes. Accordingly, we are initiating exploration of whether type 2 diabetes-induced coronary endothelial dysfunction is mediated by TNF and/or TNFRs, the elucidation of the mechanisms involved in this abnormality, and further deciphering the expression and cellular sources for TNF in Zucker diabetic fatty (ZDF, the model of type 2 diabetes) rats. The basal superoxide (O2 •−) release was significantly elevated in vessels from patients with diabetes (5). O2 •− can lead to formation of other reactive oxidative species (ROS) such as hydrogen peroxide (H2O2) and peroxynitrite (ONOO−). We also tested the mechanisms by which TNF/TNFR -induces endothelial dysfunction, and the role of ROS (O 2 •−, H2O2, ONOO−) in coronary arteries in advanced type 2 diabetes
Twenty six to thirty two weeks old, 400±50 g lean and 900±100 g ZDF (Charles Rivers) male rats were used. The ZDF rat was an inbred rat model that through genetic mutation and a managed diet of Purina 5008 will closely mimic human adult onset diabetes (type 2) and related complications. Additionally, nature and fat content of Purina 5008 diet. When fed a diet of Purina 5008, homozygous recessive males (fa/fa) developed obesity, hyperlipidemia, fasting hyperglycemia and type 2 diabetes. Homozygous dominant (+/+) and heterozygous (fa/+) lean genotypes remained normoglycemic. The ZDF rat was an accurate model for type 2 diabetes based on impaired glucose tolerance caused by the inherited obesity gene mutation, which leads to insulin resistance. Neutralizing antibody experiments were conducted on both lean Zucker (the control rat is from the same genetic background as the ZDF) and ZDF rats. We defined 26 to 32 weeks old ZDF rats as advanced type 2 diabetic rats in this study.
The neutralizing antibody to TNF (anti-TNF) (9) used in these studies is 2E2 monoclonal antibody (2E2 MAb. 94021402, NCI Biological Resources Branch). At 26–32 weeks of age, all rats received the neutralizing anti-TNF (2E2 MAb. 0.625 mg/ml/kg/day, 3 days, i.p.) (16). The rationale for this dose of antibody was based on our estimates of TNF expression (in the low ng or pg range) and this dose is able to neutralize 10–100 fold this amount of TNF.
A branch of the septal coronary artery (40 – 100 μm in diameter; ~ 0.5 mm in length) was carefully dissected for in vitro study as described previously (16). Vessels were then cannulated with glass micropipettes, pressurized to 60 cm H2O intraluminal pressure, and bathed in physiological salt solution (PSS). The inner diameters of coronary artery were measured using video microscopic techniques. After developing a stable basal tone (i.e., spontaneous constriction to 60–70% of maximal diameter), the experimental interventions were performed. The concentration-diameter relationships for ACh (0.1 nmol/L to 10 μmol/L) and SNP (1 nmol/L to 1 μmol/L) were then established. The contributions of the NO pathway in these vasodilations were examined by treating the vessels with the NOS inhibitor NG-monomethyl-L-arginine (L-NMMA, 10 μmol/L, 30-minute incubation). We tested the dose-response curve to flow-induced dilation (FID, range of ΔP [that is linearly related to flow] from 4 to 60 cm H2O), a response that is endothelial dependent, but agonist independent.
To determine whether TNF was playing a role in endothelial injury in the type 2 diabetes, endothelial dependent and independent dilation was assessed in coronary arteries from anti-TNF treated rats. To determine the role of TNF and O2 •− anion in type 2 diabetes, the above vasodilatory functions were examined in the presence of inhibitors of ROS. The contribution of NAD(P)H oxidase, xanthine oxidase and mitochondrial respiratory chain in generating O2 •− in type 2 diabetes were assessed by treating the vessels with an NAD(P)H oxidase inhibitor apocynin (10 μmol/L), a xanthine oxidase inhibitor oxypurinol (100 μmol/L) or the mitochondrial respiratory chain inhibitor rotenone (1 μmol/L) for 60-minute incubation, separately (25). All drugs were administered extraluminally in these functional studies.
The mRNA expression of TNFR1 and TNFR2 were estimated by a semiquantitative RT-PCR assay. Total RNA was extracted from isolated coronary arteries in ZDF and lean rats (4–6 vessels) using Trizol reagent (Life Technologies Inc), and was processed directly to cDNA synthesis using the SuperScript™ III Reverse Transcriptase (Life Technologies Inc). The single-strand cDNA was amplified by PCR with Taq DNA polymerase. The sequences of sense and antisense primers, respective PCR conditions, and cycle counts were as follows: TNFR1, sense: accaagtgccacaaaggaac, antisense: ctggaaatgcgtctcactca, 1min at 94°C, 1min at 55°C, and 1min at 72°C, 35 cycles; TNFR2, sense: aaatgcaagcacagatgcag, antisense: cagcagacccagagttgtca, 1 min at 94°C, 1 min at 55°C, and 1min at 72°C, 35 cycles. GAPDH cDNA was amplified as a control.
For western blot analysis, isolated coronary arteries (4–6 vessels) were separately homogenized and sonicated in lysis buffer (Cellytic MT Mammalian Tissue Lysis/Extraction Reagent, Sigma). Protein concentrations were assessed with use of BCA Protein Assay Kit (Pierce), and equal amounts of protein (40 μg) were separated by SDS-PAGE and transferred to nitrocellulose membranes (Hybond, Amersham). TNF and N-Tyr (an indicator for peroxynitrite-mediated tissue injury) protein expression were detected by western blot analysis with use of TNF primary antibodies (Santa Cruz) and N-Tyr primary antibodies (Abcam) in lean, ZDF rats, ZDF rats treated with anti-TNF (0.625 mg/ml/kg/day, 3 days, i.p.), or ZDF rats treated with TEMPOL (100 mg/kg/day, 7 days, i.p.). Horseradish peroxidase-conjugated antibodies (Abcam) were used as secondary antibodies. Signals were visualized by enhanced chemiluminescence (ECL, Amersham), and quantified by Quantity One (BioRad Versadoc imaging system).
Superoxide quantitation from the EPR spectra was determined in the homogenate (4-6 isolated coronary arteries each group) as described previously (16) in lean, ZDF rats, ZDF rats treated with anti-TNF (0.625 mg/ml/kg/day, 3 days, i.p.), or ZDF rats treated with TEMPOL (100 mg/kg/day, 7 days, i.p.).
NAD(P)H oxidase activity was assayed in protein isolated from coronary arteries extracts as initiated by the addition of 50 μmol/L N, N-dimethyl-9, 9-biacridinium dinitrate (Lucigenin) (Sigma, St. Louis, MO, USA) to the incubation mixture. Samples were counted immediately using a table top luminometer and fluorescence values were averaged from 2 minutes of stable readings for that sample. Samples from lean, ZDF rats, ZDF rats treated with anti-TNF (0.625 mg/ml/kg/day, 3 days, i.p.), or ZDF rats treated with apocynin (100 mg/kg/day, 3 days, i.p.) were run in duplicate and the NAD(P)H oxidase activity was normalized to the lean control rats.
Xanthine oxidase activity was measured by Amplex red xanthine/xanthine oxidase assay kit (A22182) from Invitrogen according to the kit protocol. Protein isolated from coronary arteries was used as the sample. Absorbance was read at 560 nm using spectrophotometer. Xanthine oxidase activity was normalized to the lean control rats.
Production of H2O2 was determined by using the Assay Kit (R & D Systems). Serum was obtained from lean, ZDF, ZDF rats treated with H2O2 inhibitor catalase (10,000 U/day, 3 days, i.p.) and ZDF rats treated with anti-TNF (0.625 mg/ml/kg/day, 3 days, i.p.). The H2O2 concentration was then determined by measuring the optical density of the solution in each well (microplate reader set to 550 nm).
At the end of each experiment, the vessel was relaxed with 100-μmol/L SNP to obtain its maximal diameter at 60 cm H2O intraluminal pressure. All diameter changes in response to agonists were normalized to the vasodilation in response to 100 μmol/L SNP and expressed as a percentage of maximal dilation. All data are presented as mean±SEM, except as specifically stated (e.g. as mean±SD for molecular study). Statistical comparisons of vasomotor responses under various treatments were performed with one-way or two-way ANOVA and intergroup differences were tested with Bonferonni Inequality. Significance was accepted at P<0.05.
Plasma parameters (Table 1) were measured at 26–32 weeks in different strains of the rats. Body weight, abdominal girth, glucose concentration and cholesterol were higher in ZDF compared with lean rats. In anti-TNF treated ZDF rats, no differences were observed in body weight, abdominal girth, blood glucose or lipid level compared with lean rats. Insulin level and blood pressure did not differ among the animals on the day of surgery.
Isolated rat coronary arteries from lean control rats dilated in a concentration-dependent manner to ACh. The NOS inhibitor, L-NMMA (10 μmol/L, 30 min) inhibited vasodilation to ACh vs control (Figure 1A). However, ACh-induced vasodilation was blunted in arteries from ZDF rats, and L-NMMA did not further affect this response (data not shown), suggesting that NO production or bioavailabilty is impaired in type 2 diabetes. Figure 1B shows abrogated FID (flow-induced dilation) in ZDF rats compared to leans. We also studied the role of TNF in the type 2 diabetes-induced vascular dysfunction. Figure 1 shows that neutralizing antibodies to TNF restored NO-mediated vasodilation (ACh-induced and flow-induced) in ZDF rats; vasodilation in lean rats remained normal (Figure 1A & 1B). This observation is the cornerstone of our hypothesis that overexpression of this inflammatory cytokine produces endothelial dysfunction in type 2 diabetes. In contrast, SNP-induced vasodilation was normal in both lean and ZDF rats (data not shown). These data indicate the vasodilation to ACh is endothelium-dependent, and NO-mediated in rat coronary arteries.
Western blot results show the protein expression of TNF was increased in isolated small coronary arteries in ZDF rat compared to lean control (Figure 2A). RT-PCR analysis showed that the mRNA expression of TNFR1 was increased significantly in ZDF rat coronary arteries (Figure 2B), but the mRNA expression of TNFR2 was not different in coronary arteries isolated from ZDF and lean rats as shown in Figure 2C. The levels of mRNA encoding for GAPDH were not found to be significantly different between groups. These results corroborate the functional results shown in Figure 1.
To establish the pathway for O2 •− production, we administered O2 •− scavenger with NAD(P)H oxidase inhibitor apocynin (10 μmol/L), xanthine oxidase inhibitor oxypurinol (100 μmol/L) or the mitochondrial respiratory chain inhibitor rotenone (1 μmol/L, data not shown), to determine if vasodilation to ACh would be restored by inhibiting of ROS in ZDF rats (Figure 3A). Administration of apocynin restored impaired vasodilation to ACh in ZDF rats; administration of apocynin+oxypurinol further restored impaired vasodilation to ACh to the lean control level in ZDF rats, but rotenone did not affect the impaired vasodilation (data not shown).
We also examined the roles of H2O2 in the presence of H2O2 inhibitor catalase (10,000U/ml) or ONOO− with ONOO− scavenger ebselen (10 μmol/L, glutathione peroxidase mimetic) in ZDF rats (Figure 3B). Ebselen or catalase also restored impaired vasodilation to ACh in ZDF rats, but did not affect the vasodilation in lean rats (data not shown).
Figure 4A showed the results from EPR spectroscopy quantifying the production of O2 •− was increased in ZDF rat compared to lean and reflect agreement with those obtained by the functional data discussed above. Figure 4B showed elevation in H2O2 production in ZDF rats compared to the lean control rats. Treatment with anti-TNF or catalase reduced H2O2 production in the ZDF rats.
NAD(P)H oxidase activity from isolated coronary arteries is normal in lean and elevated in ZDF rats (Figure 5A). The treatment of anti-TNF (0.625 mg/ml/kg/day, 3 days, i.p.) or apocynin (100 mg/kg/day, 3 days, i.p.) significantly reduced NAD(P)H oxidase activity in ZDF rats, but did not affect NAD(P)H oxidase activity in lean rats (data not shown). Figure 5B shows that xanthine oxidase activity was increased in ZDF rats, and anti-TNF attenuated xanthine oxidase activity in ZDF rats without affecting xanthine oxidase activity in lean rats (data not shown).
The short half-life of ONOO− precludes direct measurement, thus an index of its formation was obtained by western blotting for N-Tyr. Western blot analysis (Figure 6) for N-Tyr in homogenates from lean, ZDF, anti-TNF treated ZDF, and TEMPOL treated ZDF rats, revealed significantly higher levels of N-Tyr in ZDF rats, which was reduced to lean control levels by anti-TNF or TEMPOL.
Our results suggest that the over-expression of inflammatory cytokine, TNF and TNFR1 leads to oxidative stress via NAD(P)H and xanthine oxidase activation, and perhaps by activating ONOO− and H2O2, which in turn may lead to TNF expression inducing endothelial dysfunction in ZDF rats (a model for obesity and type 2 diabetes). Importantly, our findings support the concept that TNF plays a pivotal role in endothelial dysfunction in advanced type 2 diabetes based on the following observations: antibody neutralization of TNF prevented coronary endothelial dysfunction, and reduced ROS (O2 •−, ONOO•− and H2O2) production in ZDF rats. Blockade of NAD(P)H oxidase and xanthine oxidase mimicked the actions of anti-TNF on endothelial function in ZDF rats. Molecular evidence indicated that the expression of TNF and TNFR1, production of ROS (O2 •−, H2O2, and ONOO−), NAD(P)H oxidase and xanthine oxidase activity were significantly increased in ZDF rats; but, administration of anti-TNF to ZDF rats attenuated NAD(P)H oxidase activity and xanthine oxidase activity. Our findings indicate that TNF contributes to endothelial dysfunction in type 2 diabetes via increasing ONOO−, H2O2, and O2 •−.
Understanding endothelial dysfunction is critical because this condition precedes the development of diabetic vascular disease; thus if endothelial dysfunction can be rectified, the progression of vascular disease may be halted. Accordingly, we determined the role of TNF in endothelial function in ZDF rats by establishing the expression of this cytokine and its receptors, and production of ROS. Clinical and experimental studies have demonstrated that cardiac pump function is compromised in type 2 diabetes, suggesting that alterations in cardiac tissue metabolism in the diabetic state are responsible for this impairment (14). Changes in coronary vascular function can lead to a mismatch of myocardial supply and demand, thereby provoking ischemic episodes in the diabetic heart. In humans, vasodilation of coronary arteries was also altered after pharmacological (ACh) or mechanical (cold test) stimuli, but these abnormalities of large vessels were not associated with angiographic lesions, and are independent of other cardiovascular risk factors (1), suggesting impaired endothelial function without any anatomical lesions. Bagi et al. (1) have described that agonist- and flow-induced dilation of coronary arteries was impaired in type 2 diabetic mice. Furthermore, Miura et al. (12) confirmed the impairment of coronary microvascular function in human coronary arteries isolated from patients affected by type 1 or type 2 diabetes mellitus: coronary arteries showed a reduced vasodilation to hypoxia due to a reduced activity of ATP-sensitive potassium channels. Our results are consistent with these studies: in ZDF rats, dilation to ACh, or flow, was blunted compared to lean rats, but SNP-induced dilation was comparable. Neutralizing antibodies to TNF, or blockade of NAD(P)H oxidase and xanthine oxidase, partially restored endothelium-dependent, NO-mediated coronary arteriolar dilation in ZDF rats, but the antibodies to TNF did not alter the vasodilation in lean rats.
Yudkin et al. (24) showed that CRP, IL-6 and TNF are elevated in association with quantitative measures of insulin resistance and features of the insulin resistance syndrome. Rask-Madsen et al. (17) have recently demonstrated that TNF is able to inhibit insulin-stimulated glucose uptake as well as endothelium-dependent vasodilation in humans and that inhibitory effect on vasodilator function is larger during local elevation of plasma insulin; the authors also speculated that TNF blocked NO production stimulated by insulin and ACh. TNF inhibits NO-mediated endothelium-dependent vasorelaxation in small coronary arteries via sphingomyelinase activation and consequent O2 •− production in endothelial cells (26). Gilmont et al. have shown a direct effect of TNF on endothelial cells, whereby the cells are rendered more susceptible to oxidant injury accompanying reperfusion in rat pulmonary artery endothelial cells (3).
Our RT-PCR analysis demonstrated that TNFR1 and TNFR2 mRNA were detected in the hearts and isolated small coronary arteries from lean and ZDF rats. The diverse signaling events that regulate varied TNF responses are all initiated by the binding of heterotrimeric ligand to one of two cell surface receptors (TNFR1 and TNFR2) (23). The connection between TNF and type 2 diabetes-induced endothelial dysfunction was established in the functional results (anti-TNF restored endothelium-dependent vasodilation in ZDF rats). We found that the expression of TNF is elevated in isolated coronary arteries in ZDF rats compared to lean controls. We also found that the expression of the TNF receptor, TNFR1 (but not TNFR2) was elevated in ZDF rats compared to lean rats.
It is provocative to note that despite the similarities in glucose, body weight, lipid level, insulin resistance, and blood pressure in the advanced diabetic animals, endothelial function was better in ZDF treated with anti-TNF than in the control. This suggests that TNF is the key cytokine, which induced endothelial dysfunction in the advanced type 2 diabetes (26 to 32 weeks old ZDF rats). These results are also consistent with our previous study on Zucker obese fatty rats (16), and provide new information under more advanced pathophysiological conditions, regarding the role of TNF in endothelial dysfunction in type 2 diabetes and the mechanisms by which TNF induces these pathophysiological conditions. Type 2 diabetes-induced coronary endothelial dysfunction were mediated by TNF and we further investigated the causal mechanisms.
TNF stimulates O2 •− production in neutrophils and endothelial cells, reportedly via ceramide-activated protein kinase (CAPK), NAD(P)H oxidase, xanthine oxidase, or NO synthase, etc. (18,26). Diabetes has been associated with an increased generation of oxygen free radicals as well. Many experimental studies suggest that increased O2 •− production accounts for a significant proportion of the NO deficit in diabetic vessels. Potential sources of vascular O2 •− production include NAD(P)H-dependent oxidases, xanthine oxidase, lipoxygenase, mitochondrial oxidase and NO synthase. NAD(P)H oxidases appear to be the principal source of O2 •− production in several animal models of vascular disease, including diabetes (7, 18, 26). Furthermore, NAD(P)H oxidase proteins and activity are present in human blood vessels, including atherosclerotic coronary arteries, and in saphenous veins and mammary arteries from patients with coronary artery disease, which suggests that this oxidase system plays an important role in cardiovascular disease (2). Guzik et al.(5) have described the mechanisms of increased O2 •− production in human diabetes mellitus. They found that basal O2 •− release was significantly elevated in vessels from patients with diabetes: Western blot analysis showed increased levels of the p22 phox membrane-bound subunit and the p67 phox and p47 phox cytosolic subunits in both veins and arteries from diabetic patients. The impaired endothelial function may be the direct result of the overproduction of O2 •− during the development of type 2 diabetes. O2 •− is the chemical precursor to many ROS, such as H2O2, and ONOO−. H2O2 is formed by the spontaneous or enzymatic dismutation (via superoxide dismutase) of O2 •− and is in itself a potent oxidant. ONOO− is formed by the reaction between NO and O2 •− and is another potent oxidant. Our study shows that in addition to O2 •−, the production of H2O2 and ONOO− were also higher in ZDF rats, indicating ROS plays a significant role in advanced type 2 diabetes.
To establish if NAD(P)H oxidase, xanthine oxidase and/or mitochondraia respiratory chain are the pathway for O2 •− production, we administered the NAD(P)H oxidase inhibitor, apocynin, to determine if vasodilation to ACh would be restored in ZDF rats. Our results showed that apocynin and oxypurinol rescued dilation to ACh in ZDF rats, but did not affect the response in lean rats. These results demonstrated that the greater amount of generation of O2 •− in ZDF rats is also attributed to activation of xanthine oxidase, which is downstream from sphingomyelinase. Taken together, our results further support that TNF and O2 •− are connected in the production of oxidative stress and endothelial dysfunction in type 2 diabetes. Our results regarding type 2 diabetes diverge when considering the enzyme system responsible for this pathophysiological disease. In our previous study in prediabetic metabolic syndrome (16), we found NAD(P)H oxidase assumed prominence in O2 •− generation, but that in type 2 diabetes, an increased amount of superoxides were generated by both NAD(P)H and xanthine oxidases.
It has been reported that O2 •− and NO combine to form peroxynitrite, and limiting production of O2 •− thus increase the bioavailability and measurements of NO. In our study, antibodies to TNF attenuates O2 •−, H2O2, and ONOO− production in ZDF rats. We found that inhibition of both xanthine oxidase and NAD(P)H oxidase are required to block ROS production in ZDF rats. We believe that the production of authentic NO increases following inhibition of xanthine oxidase and NAD(P)H oxidase in the ZDF rats. Our previous study (16) suggested TNF contributes to endothelial dysfunction in prediabetic metabolic syndrome (Zucker obese fatty rats, young group of the rats at 12–16 weeks) and in 12–16 weeks leprdb mice (young type 2 diabetic mouse models), and that anti-TNF may rescue this impairment. However, this was not the situation in the more advanced condition of type 2 diabetes (26–32 weeks of ZDF rats). We found that the severe impaired vasodilation to ACh resulted from increased expression/production of TNF in type 2 diabetes, which stimulates endothelial generation of O2 •− radicals via NAD(P)H oxidase and xanthine oxidase in the microvasculature and contributes to the observed endothelial dysfunction. Our results demonstrate that the endothelial dysfunction occurring in type 2 diabetes is the result of effects of the inflammatory cytokine TNF and mainly through the over-expression of TNFR1. Selective modulation of TNF and its receptor signaling may provide a novel therapeutic target to remediate coronary diseases associated with TNF activation. It is reported (27) that oxidative stress mediated by hyperglycaemia-induced generation of reactive oxygen species (ROS) contributes significantly to the development and progression of diabetes and related vascular complications. NAD(P)H oxidase has been implicated as the major source of ROS generation in the vasculature in response to high glucose and advanced glycation end-products. Sustained activation of NAD(P)H oxidase in diabetes may diminish intracellular levels of NADPH, an essential cofactor for endothelial NO synthase (eNOS) and several antioxidant systems. Recent evidence suggests that basal ROS production via NAD(P)H oxidase may upregulate antioxidant enzyme defenses via redox signalling. (27)
Knowledge gained from this study may help to further understand the increased cardiovascular risk and development of chronic vascular disease in diabetes. The inflammatory cytokine, TNF, plays a pivotal role in endothelial dysfunction in diabetes. This work may provide exciting new targets for the development of drugs for cardiovascular disorders in ischemic heart disease, obesity, diabetes and hypertension.
This study was supported by grants from American Heart Association Scientist Development Grant (110350047A), Pfizer Atorvastatin Research Award (2004-37), NIH grants (RO1-HL077566 and RO1-HL085119) to Dr. Cuihua Zhang.